Rebamipide, a gastroprotective drug, was developed in Japan for the treatment of peptic
ulcer disease. It was proven superior to the former same category drug cetraxate in a …

Gastric cancer is one of the leading causes of the cancer-related mortality worldwide. The
etiology of this disease is complex and involves genetic predisposition and environmental …

Background & Aims The association between cellular senescence and Helicobacter pylori–
induced atrophic gastritis is not clear. Here, we explore the role of cellular senescence in H …

Purpose.: TNF-α disrupts the barrier function of cultured human corneal epithelial (HCE)
cells. We investigated the effects of the cytoprotective drug rebamipide on this barrier …

Частое поражения органов пищеварения при новой коронавирусной инфекции, а также
ее сочетание с гастроэнтерологической патологией усложняет весь комплекс лечебно …

The extended infection with Helicobacter pylori (H. pylori), one of the most frequent
infectious agents in humans, may cause gastritis, peptic ulcers, gastric mucosa-associated …

The aim of the study was to investigate the effects of rebamipide on symptom, histology,
endogenous prostaglandin, and mucosal oxygen free radicals in chronic erosive gastritis …

H. pylori infection causes gastritis, peptic ulcers and gastric cancer. Eradicating H. pylori
prevents ulcers, but to what extent this prevents cancer remains unknown, especially if given …

Rebamipide (Reba), a gastroprotective drug, has signified its hepatoprotective activity;
however, its possible post-therapeutic intervention in hepatic ischemia/reperfusion (I/R) …

Purpose: To determine if the gastroprotective drug OPC-12759 increased proliferation of rat
conjunctival goblet cells in culture. Methods: Cultured goblet cells were incubated with 10 …